Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The microbiome across the prostate disease continuum: from health and BPH to prostatitis/CPPS and cancer.

Oncogene·2026
Same author

ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis.

Signal transduction and targeted therapy·2026
Same author

BTAF1: a key regulator of DNA end resection and predictor of chemotherapy sensitivity in gastric cancer.

Cell death and differentiation·2026
Same author

NIPAL1 Drives a Metabolic-Epigenetic Feedback Loop to Promote Lactate-Mediated Immune Evasion in Esophageal Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

SDC1<sup>+</sup> CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers.

Gut·2026
Same author

Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: May 11, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.4K

Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to

Jiarong Zhan1, Mengqing Li2, Lei Li3

  • 1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Cancer Research
|April 17, 2025
PubMed
Summary

Latent transforming growth factor β binding protein 2 (LTBP2) is secreted by cancer-associated fibroblasts (CAFs) in esophageal squamous cell carcinoma (ESCC). Targeting LTBP2 enhances chemotherapy effectiveness by reducing cancer cell metastasis and chemoresistance.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Related Experiment Videos

Last Updated: May 11, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Area of Science:

  • Oncology
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment.
  • CAFs influence cancer aggressiveness via secreted factors, necessitating identification of specific CAF-derived pro-tumorigenic molecules.
  • Understanding CAF-secreted factors can reveal therapeutic targets to disrupt tumor progression.

Purpose of the Study:

  • To identify unique proteins secreted by esophageal squamous cell carcinoma (ESCC) CAFs that drive tumor progression.
  • To characterize the role of identified proteins in promoting ESCC metastasis and chemoresistance.
  • To evaluate the therapeutic potential of targeting these proteins to enhance chemotherapeutic efficacy.

Main Methods:

  • Proteomic analysis to identify unique CAF secretions in ESCC.
  • In vitro and in vivo experiments to assess the function of identified proteins in metastasis and chemoresistance.
  • Investigation of molecular mechanisms, including protein-protein interactions and signaling pathway activation (e.g., Src signaling).
  • Assessment of therapeutic efficacy using antagonistic antibodies targeting the identified protein.

Main Results:

  • Latent transforming growth factor β binding protein 2 (LTBP2) was identified as a unique protein secreted exclusively by ESCC CAFs.
  • LTBP2 promotes ESCC metastasis and chemoresistance by interacting with integrin α6β4 and activating Src signaling.
  • Targeting LTBP2 with antagonistic antibodies significantly increased the sensitivity of ESCC cells to chemotherapy.

Conclusions:

  • LTBP2 is a critical mediator of CAF-driven cancer cell aggression in ESCC.
  • LTBP2 represents a promising therapeutic target for enhancing chemotherapeutic efficacy in ESCC.
  • Targeting CAF-secreted factors like LTBP2 offers a novel strategy to overcome treatment resistance in cancer.